Clinical Trial Update: Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating a neoepitope-based personalized DNA vaccine in pediatric patients with recurrent central nervous system tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumors
• Central Nervous System Neoplasms

Drugs mentioned

• Neoepitope-based Personalized DNA Vaccine

Snippet

Sponsor: Washington University School of Medicine | Conditions: Pediatric Recurrent Central Nervous System Tumors | Phase 1 | Status: RECRUITING